/ /

LATEST

Neuroprotective strategy primed for progress
Neuroprotective strategy primed for progressAdvancing methods for evaluating therapeutic response have fostered a new era in glaucoma neuroprotection in which promising candidates are already being investigated in clinical trials and others are poised to begin phase I testing, said Jeffrey L. Goldberg, MD, PhD.
Fixed-combination glaucoma agent yields positive safety, efficacy dataA phase III trial for the fixed-combination netarsudil/latanoprost agent (Roclatan, Aerie Pharmaceuticals)reports positive results. The company plans to submit a NDA for the drug in early 2018.
ABiC viable option for different stages severities of glaucomaWith its ability to restore the eye’s natural outflow pathway, ab-interno canaloplasty (ABiC) presents a viable option for the treatment of different stages and severities of glaucoma, according to Mark J. Gallardo, MD.
IOP fluctuations important factor in setting patients’ target pressureWhen setting a target IOP for patients with glaucoma, consideration of IOP fluctuations and the degree to which they vary is important.
What to do when the clinic has taken you hostage
What to do when the clinic has taken you hostageA dysfunctional clinic environment may mean the power lies with employees instead of the administration. Be aware of common complaints so the power of the practice  can be taken back.
Early surgical intervention with stent advantageous for certain glaucomasIt is well known that with most disease, the earlier it is detected, the better the outcome prognosis. Along with early detection comes the need for early treatment. Traditionally, options for glaucoma have been limited. Medications can be effective when used properly, though patients are notorious for compliance issues.
May the force be with you, too
May the force be with you, tooTomasso, a vitreoretinal surgeon, recently shared a blog by someone who calls him/herself “Neuroskeptic”.Neuroskeptic penned a spoof “scientific” article about midichlorians, which are the little organisms inside cells that give Jedi Knights (the good guys in the “Star Wars” movies) their powers (and unfortunately, confer those same powers to certain bad guys, like Darth Vader).
Taking on surgery in HSV patients
Taking on surgery in HSV patientsCataract and refractive surgeons should use prophylaxis to avoid reactivation of the herpes simplex virus (HSV) in patients with a history of infection with this virus, according to Elizabeth Yeu, MD.
Cenegermin receives European Commission marketing authorizationThe European Commission has granted marketing authorisation for cenegermin eye drops (Oxervate, Dompé) for the treatment of moderate to severe neurotrophic keratitis.
Risk factors for rapid glaucoma progressionPublished in the American Journal of Ophthalmology, a retrospective case-controlled study between cohorts of rapid glaucoma disease progressors and nonrapid progressors found that rapid progressors were older, had significantly lower central corneal thickness, and baseline intraocular pressures.

Poll

View Results